DUBLIN, May 21, 2020 /PRNewswire/ — The “APAC Biologics CMO Directory” report has been added to ResearchAndMarkets.com’s offering.
Research and Markets Logo
Ten years ago, it was hard for Chinese biopharmaceutical service companies to meet the requirements of a Western client. Today, there is a proliferation of companies such as WuXi Biologics, MabPlex, JHL Biotech and more. Furthermore, recently in Asia:
Eirgenix received approval from Japan’s PMDA, opportuning it to sell to the Japanese market.
Korea’s Celltrion has budgeted $514 million over five years to build China’s biggest biologics facility at a capacity of 120,000 litres, manufacturing Celltrion’s own biologics and performing contract work for Chinese biotechs.
New mammalian production lines established by AGC biologics to produce monoclonal antibodies (MAbs) and fusion proteins
Contract biomanufacturing in Asia is poised for growth.